|
|
|
|
|
Effects of ulinastatin on serum procalcitonin, C reactive protein and immune function in patients with sepsis complicated with multiple organ failure |
Zhang Kai-kai, Yu Xue-zhong, Liang Xian-quan, Yu Shan-shan |
Guiyang Second People′s Hospital, Guiyang 550023, China |
|
|
Abstract Objective To analyze the effects of ulinastatin on serum procalcitonin (PCT), C reactive protein (CRP) and immune function in patients with sepsis complicated with multiple organ failure. Methods From March 2014 to March 2017, 157 cases of sepsis with multiple organ failure in intensive care unit of Guiyang Second People′s Hospital were retrospectively selected. According to drug use, it was divided into control group and observation group. The patients in the control group were treated with routine therapy, while the patients in the observation group were treated with routine therapy combined with ulinastatin. APACHEⅡ the score, the mortality rate within 1 months, immune function, heart function index, PCT, CRP, lipid peroxide (LPO) and monocyte human leukocyte antigen DR (HLA-DR) level changes in the patientswere observed and analyzed between the two groups. Results APACHEⅡ score of the two groups were improved compared with before treatment, patients in the observation group after treatment APACHEⅡ score than the control group (P<0.05). After treatment, PCT, CRP, LPO, BNP, hla-dr and LVEF levels of the observation group were respectively (9.75±3.64) ng/mL, (9.11±3.91) mg/L, (4.10±1.69) EU/mL, (285.55±87.79) pg/mL, (26.94±4.02) %, (66.87±5.28) %; they were (9.87±3.55) ng/mL, (13.97±4.87) mg/L, (8.11±2.14) EU/mL, (311.01±95.25) pg/mL, (20.68±3.22) %, (55.48±6.34) %, respectively in control group; there were statistically significant differences in CRP, LPO, BNP, hla-dr and LVEF levels between the two groups, but there was no statistical difference in PCT level (P> 0.05).The level of immune function in the observation group was better than that in the control group (P<0.05).The mortality of the patients in the observation group was 18.29 in one month and that in the control group was 44.00. The fatality rate in the observation group was lower than that in the control group (P<0.05). Conclusion Ulinastatin adjuvant treatment of sepsis with multiple organ failure can improve the heart function of patients, regulate the level of immune indicators, reduce the serum levels of CRP and LPO, and reduce the short-term mortality.
|
|
Corresponding Authors:
Yu Xue-zhong, E-mail:yxzpumch@126.com
|
|
|
|
[1]孙小聪,邵义明,黄河,等. 乌司他丁对脓毒症急性肾损伤肾功能的保护作用[J]. 中华实验外科杂志,2015, 32(4):910-912.
[2]尹海燕,陶珮,叶小玲,等. 乌司他丁对老年脓毒症患者肠屏障功能的保护[J]. 中华急诊医学杂志, 2016, 25(2):177-181.
[3]叶小玲,陶珮,尹海燕,等. 不同剂量乌司他丁对老年脓毒症患者肠黏膜屏障功能保护作用的评价[J]. 广东医学, 2016, 37(06):908-911.
[4]易梦秋,余旻. 脓毒症导致多器官功能障碍的发病机制[J]. 实用医学杂志, 2016, 32(20):3451-3454.
[5]唐虹. 乌司他丁、血必净联合治疗对烧伤后脓毒症凝血功能及全身炎性反应影响的临床研究[J]. 中国医科大学学报, 2015, 44(12):1132-1136.
[6]刘赟,吴星恒. 乌司他丁干预对脓毒症幼鼠血清肿瘤坏死因子-α、P-选择素和凝血酶抗凝血酶复合物水平的影响[J]. 中国当代儿科杂志, 2017, 19(2):237-241.
[7]陈伟,胡志华,杨远征. 乌司他丁辅助高容量血液滤过对严重脓毒血症血清细胞黏附分子-1、胆碱酯酶和凝血功能的影响[J]. 中国现代医学杂志, 2016, 26(11):54-58.
[8]姚艳粉. 乌司他丁对脓毒症急性肾损伤患者心钠肽、尿肾损伤分子-1以及血清半胱氨酸蛋白酶抑制剂的影响[J]. 中国现代医学杂志, 2016, 26(4):71-75.
[9]Ashby J, Karlsson K. DEFINITIONS OF GENDER RESEARCH FOR CRP GENDER BUDGET[J]. Applied Physics Letters, 2015, 74(13):1898-1900.
[10]Ridker PM. From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection[J]. Circulation Research, 2016, 118(1):145-156.
[11]Nimptsch K, Aleksandrova K, Boeing H, et al. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk[J]. International Journal of Cancer, 2015, 136(5):1181-1192.
[12]Pinet VM, Long EO. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes[J]. European Journal of Immunology, 2015, 28(3):799-804.
[13]Jordanova ES, Philippo K,Giphart MJ, et al. Mutations in the HLA class Ⅱ genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma[J]. Immunogenetics, 2015, 55(4):203-209.
[14]Hu X, Deutsch AJ, Lenz TL, et al. Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk[J]. Nature Genetics, 2015, 47(8):898-905. |
|
|
|